+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 1Year - 18Years
All Genders
ID06848569

Phase II Study of Sintilimab Plus AVD Chemotherapy for Children and Teens with Low to Moderate Risk Classical Hodgkin Lymphoma

Led by Sun Yat-sen University · Updated on 2025-02-27

73

Participants Needed

1

Research Sites

208 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the combination of sintilimab and AVD chemotherapy in treating children and adolescents aged 1 to 18 years with low-to-intermediate risk classical Hodgkin lymphoma. This phase II trial focuses on patients newly diagnosed with this type of lymphoma, classified by the Ann Arbor staging system, aiming to assess both the effectiveness and safety of this treatment approach. Participants will receive sintilimab together with AVD chemotherapy every two weeks for between four and six cycles. The study is conducted at multiple centers and follows a single treatment group design without comparison groups. The treatment plan is designed to target the lymphoma while monitoring patients closely throughout the therapy period. During the trial, participants will be monitored through clinical visits, laboratory tests including blood counts and liver and kidney function, and assessments of physical condition using scores like the Lansky and Karnofsky scales. Researchers will track event-free survival for four years as the primary outcome. Parents or guardians will provide informed consent, and ongoing safety and treatment adherence will be observed throughout the studys duration.

CONDITIONS

Brief Title

Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study

Research Team

Y

Yizhuo Zhang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here